Daprodustat Patent Expiration

Daprodustat is Used for managing anemia associated with chronic kidney disease. It was first introduced by Glaxosmithkline Intellectual Property No 2 Ltd England in its drug Jesduvroq on Feb 1, 2023.

Daprodustat Patents

Given below is the list of patents protecting Daprodustat, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Jesduvroq	US11117871	Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof	Mar 13, 2038	Glaxosmithkline
Jesduvroq	US11649217	Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof	Mar 13, 2038	Glaxosmithkline
Jesduvroq	US8324208	Prolyl hydroxylase inhibitors	Dec 11, 2028	Glaxosmithkline
Jesduvroq	US11643397	Prolyl hydroxylase inhibitors	Jun 22, 2027	Glaxosmithkline
Jesduvroq	US8557834	Prolyl hydroxylase inhibitors	Jun 22, 2027	Glaxosmithkline
Jesduvroq	US8815884	Prolyl hydroxylase inhibitors	Jun 22, 2027	Glaxosmithkline

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List